Keyword search (3,448 papers available) |
Author(s): Mohammad K, Baratang Junio JA, Tafakori T, Orfanos E, Titorenko VI
Int J Mol Sci. 2020 Jul 02;21(13): Authors: Mohammad K, Baratang Junio JA, Tafakori T, Orfanos E, Titorenko VI
Article GUID: 32630624
Author(s): Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M
Int J Mol Sci. 2019 Dec 05;20(24): Authors: Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M
Article GUID: 31817343
Author(s): Titorenko VI
Int J Mol Sci. 2019 Jul 03;20(13): Authors: Titorenko VI
Article GUID: 31277345
Author(s): Malkawi AK; Masood A; Shinwari Z; Jacob M; Benabdelkamel H; Matic G; Almuhanna F; Dasouki M; Alaiya AA; Rahman AMA;...
Prolonged dexamethasone (Dex) administration leads to serious adverse and decrease brain and heart size, muscular atrophy, hemorrhagic liver, and presence of kidney cysts. Herein, we used an untarg...
Article GUID: 31247941
Author(s): Mohammad K, Dakik P, Medkour Y, McAuley M, Mitrofanova D, Titorenko VI
Int J Mol Sci. 2018 Mar 15;19(3): Authors: Mohammad K, Dakik P, Medkour Y, McAuley M, Mitrofanova D, Titorenko VI
Article GUID: 29543708
Author(s): Titorenko VI
Int J Mol Sci. 2018 Jul 14;19(7): Authors: Titorenko VI PMID: 30011889 [PubMed - indexed for MEDLINE]
Article GUID: 30011889
Author(s): Busby M, Hallett MT, Plante I
Int J Mol Sci. 2018 Feb 28;19(3): Authors: Busby M, Hallett MT, Plante I
Article GUID: 29495625
Author(s): Mohammad K, Dakik P, Medkour Y, Mitrofanova D, Titorenko VI
Int J Mol Sci. 2019 May 01;20(9): Authors: Mohammad K, Dakik P, Medkour Y, Mitrofanova D, Titorenko VI
Article GUID: 31052375
Title: | Proteomic Analysis of Morphologically Changed Tissues after Prolonged Dexamethasone Treatment |
Authors: | Malkawi AK, Masood A, Shinwari Z, Jacob M, Benabdelkamel H, Matic G, Almuhanna F, Dasouki M, Alaiya AA, Rahman AMA, |
Link: | https://pubmed.ncbi.nlm.nih.gov/31247941/ |
DOI: | 10.3390/ijms20133122 |
Category: | Int J Mol Sci |
PMID: | 31247941 |
Dept Affiliation: | CHEMBIOCHEM
1 Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrook Street West, Montréal, QC H4B 1R6, Canada. 2 Department of Comparative Medicine, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 3 Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925 (98), Riyadh 11461, Saudi Arabia. 4 Stem Cell & Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 5 Department of Genetics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. 6 College of Public Health, Medical, and Veterinary Sciences/Molecular & Cell Biology, James Cook University, Townsville, QLD 4811, Australia. 7 Department of Genetics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11461, Saudi Arabia. aabdelrahman46@kfshrc.edu.sa. 8 College of Medicine, Al Faisal University, Riyadh 11533, Saudi Arabia. aabdelrahman46@kfshrc.edu.sa. 9 Department of Chemistry, Memorial University of Newfoundland, St. John's, NL A1B 3X7, Canada. aabdelrahman46@kfshrc.edu.sa. |
Description: |
Prolonged dexamethasone (Dex) administration leads to serious adverse and decrease brain and heart size, muscular atrophy, hemorrhagic liver, and presence of kidney cysts. Herein, we used an untargeted proteomic approach using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for simultaneous identification of changes in proteomes of the major organs in Sprague-Dawley (SD rats post Dex treatment. The comparative and quantitative proteomic analysis of the brain, heart, muscle, liver, and kidney tissues revealed differential expression of proteins (n = 190, 193, 39, 230, and 53, respectively) between Dex-treated and control rats. Functional network analysis using ingenuity pathway analysis (IPA revealed significant differences in regulation of metabolic pathways within the morphologically changed organs that related to: (i) brain-cell morphology, nervous system development, and function and neurological disease; (ii) heart-cellular development, cellular function and maintenance, connective tissue development and function; (iii) skeletal muscle-nucleic acid metabolism, and small molecule biochemical pathways; (iv) liver-lipid metabolism, small molecular biochemistry, and nucleic acid metabolism; and (v) kidney-drug metabolism, organism injury and abnormalities, and renal damage. Our study provides a comprehensive description of the organ-specific proteomic profilesand differentially altered biochemical pathways, after prolonged Dex treatement to understand the molecular basis for development of side effects. |